TY - JOUR
T1 - Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer
AU - Yap, Hwee‐Yong ‐Y
AU - Hortobagyi, Gabriel N.
AU - Blumenschein, George R.
AU - Tashima, Charles K.
AU - Buzdar, Aman U.
AU - Krutchik, Allan N.
AU - Benjamin, Robert S.
AU - Gutterman, Jordan U.
AU - Bodey, Gerald P.
PY - 1979
Y1 - 1979
N2 - Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85% and a median duration of response of 25 months. Response rate of 69% and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87% and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.
AB - Ninety‐eight premenopausal patients with stage IV breast cancer were treated with chemoimmunotherapy alone, or with combination oophorectomy – chemoimmunotherapy either simultaneously (chemoimmunotherapy within four weeks of oophorectomy) or sequentially (delayed chemoimmunotherapy until evidence of progressive disease or no response to oophorectomy). The chemoimmunotherapy consisted of a three‐drug combination of Adriamycin, cyclophosphamide, and 5‐fluorouracil or Ftorafur; immunotherapy consisted of either oral levamisole, BCG by scarification, or a combination of both. Forty patients underwent simultaneous oophorectomy–chemoimmunotherapy, with a response rate of 85% and a median duration of response of 25 months. Response rate of 69% and a median duration of response of 16.6 months was observed with the 29 patients who received sequential oophorectomy–chemoimmunotherapy. Another 29 patients were treated with chemoimmunotherapy alone and achieved a response rate of 87% and a median duration of response of 11.8 months. Though there were no significant differences in the response rate, patients treated with chemoimmunotherapy alone had a significantly shorter median duration of response (P < 0.05). This would suggest that oophorectomy in combination with chemoimmunotherapy is the most favorable treatment modality for premenopausal patients with advanced metastatic breast cancer.
KW - combined chemoimmunotherapy for breast cancer
UR - http://www.scopus.com/inward/record.url?scp=0018687866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018687866&partnerID=8YFLogxK
U2 - 10.1002/jso.2930120407
DO - 10.1002/jso.2930120407
M3 - Article
C2 - 392197
AN - SCOPUS:0018687866
SN - 0022-4790
VL - 12
SP - 333
EP - 341
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 4
ER -